Browsing by Subject "Meglumine antimoniate"

Alterations in evoked otoacoustic emissions by the use of meglumine antimoniate in American tegumentary leishmaniasis patients

Bezerra, Débora Cristina de Oliveira et al. | Date Issued: 2017

Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial

Mendes, Luciana et al. | Date Issued: 2021

Combined therapy with adipose tissuederived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis

Ramos, Tadeu Diniz et al. | Date Issued: 2020

Comparação da evolução das lesões de leishmaniose cutânea após tratamento com antimoniato de meglumina (5 ou 20 mg Sb5+

Gonçalves, Julia Costa de Faria | Date Issued: 2018

Introdução: A leishmaniose cutânea (LC) é a forma clínica mais comum das leishmanioses no Brasil e a medicação padrão pelo Ministério da Saúde (MS) é o antimoniato de meglumina (AM), 10 a 20 mg Sb5+/kg/dia por via intramuscular ...

Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit

Duque, Maria Cristina de Oliveira et al. | Date Issued: 2019

Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis

Kato, Kelly Cristina et al. | Date Issued: 2018

Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis

Peixoto, Juliana Figueiredo et al. | Date Issued: 2024

Epoxy-α-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB/c – Leishmania (Leishmania) amazonensis

Peixoto, Juliana Figueiredo et al. | Date Issued: 2024

Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil

Carvalho, Janaína de Pina et al. | Date Issued: 2021

Estudo comparativo entre estibogluconato de sódio BP 88© e antimoniato de meglumina no tratamento da leishmaniose cutânea: Toxidade bioquímica e cardíaca / Comparative study between sodium stibogluconate BP 88© and meglumine antimoniate in cutaneous leishmaniasis treatment: Biochemical and cardiac toxicity

Saldanha, Ana Cristina Rodrigues et al. | Date Issued: 2000

Foi avaliada a toxicidade de dois antimoniais pentavalentes em 111 pacientes com leishmaniose cutânea. Quarenta e sete pacientes receberam antimoniato de meglumina (Grupo I) B 64 pacientes, estibogluconato de sódio BP 88© ...

Evidence for Tissue Toxicity in BALB/c Exposed to a Long-Term Treatment with Oxiranes Compared to Meglumine Antimoniate

Oliveira, Luiz Filipe Gonçalves et al. | Date Issued: 2017

Favorable responses to treatment with 5 mg Sbv /kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions

Cataldo, Jamyra Iglesias et al. | Date Issued: 2018

Improved treatment outcome following the use of awound dressings in cutaneous leishmaniasis lesions

Borba, Pedro B. et al. | Date Issued: 2024

Infiltração intralesional de antimoniato de meglumina para tratamento de leishmaniose cutânea localizada: revisão sistemática, metanálise e análise de custo-efetividade

Brito, Nayara Castelano | Date Issued: 2019

A leishmaniose tegumentar (LC) é uma doença complexa e de epidemiologia, etiologia, patologia e características clínicas variáveis. A base do tratamento ainda são os derivados de antimônio pentavalente (Sbv), administrados ...

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities

Pimentel, Maria Inês Fernandes et al. | Date Issued: 2017

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)

Brahim, Lucia Regina et al. | Date Issued: 2017

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial

Ramalho, Dario Brock et al. | Date Issued: 2018

Mucosal leishmaniasis: the experience of a Brazilian referral center

Pedras, Mariana Junqueira et al. | Date Issued: 2018

Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis

Lyra, Marcelo Rosandiski et al. | Date Issued: 2016

Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil.

Toledo Junior, Antonio et al. | Date Issued: 2014